Business Context and Reporting Period
This Form 8-K Current Report was filed by Ruthigen, Inc. (not Pulmatrix, Inc.) on March 2, 2015, covering events occurring on February 27, 2015. The filing addresses corporate governance changes under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
- Board Appointment: Akihisa Akao was appointed as a Class II director and a member of the Audit Committee, effective February 27, 2015.
- Committee Resignation: Hojabr Alimi, the Company's Chief Executive Officer, resigned as a member of the Audit Committee, effective February 27, 2015.
Management Commentary and Risks
Mr. Akao brings 38 years of healthcare industry experience, including roles in pulmonology, wound care, and cardiovascular therapies. He previously served as CEO of White Moon Medical, Inc. and held leadership positions at Power Medical Interventions Inc. prior to its merger with Covidien. The filing states there is no arrangement regarding Mr. Akao's compensation for serving as a director and no understanding regarding his selection.
Investor Verification Checklist
- Verify the registrant name is Ruthigen, Inc., not Pulmatrix, Inc.
- Confirm the effective date of the board changes (February 27, 2015).
- Review Mr. Akao's background for potential conflicts of interest given his prior roles in the medical device sector.
- Check subsequent filings for any compensation agreements with the new director.